To use all functions of this page, please activate cookies in your browser.
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Sanofi-aventis to acquire Oenobiol
11-03-2009: Sanofi-aventis announced that it has entered into an agreement to acquire the company Laboratoire Oenobiol, manufacturer of nutritional, health and beauty supplements. In 2009, Oenobiol had a turnover of 57.2 million Euros, 85% of which was in France and 15% in other countries, primarily in Italy, Spain, Belgium, Poland and Portugal.
"The acquisition of Oenobiol will complete and reinforce our presence on the French market and is fully in line with sanofi-aventis’ strategy to become a global and diversified healthcare leader", declared Nicolas Cartier, General Manager of sanofi-aventis France. "This emblematic brand is well-known and conveys an image of quality and trust, with a strong scientific backing. We are very happy to welcome the women and men of Laboratoire Oenobiol into the sanofi-aventis family, to benefit from their skills while giving them access to sanofi-aventis’ healthcare expertise and development resources" he added.
Dr. Marie Béjot, nutritionist and founder of Laboratoire Oenobiol, will remain highly involved in the strategy and development of the Oenobiol line. She will co-lead a Strategic Committee and a Nutritional Supplement Development Committee within sanofi-aventis.
Contact / Request information
Request further information free of charge:
Watchlist
This is where you can add this news to your personal favourites
- 1Drug companies enter Indonesia and the Philippines
- 2Glucose uptake relies on newly identified protein
- 3Nexia Biotechnologies to reorganize into oil and gas company
- 4Pharmexa A/S sells Pharmexa-Epimmune to the Korean company VaxOnco, Inc.
- 5Bayer acquires exclusive rights to Bioton’s insulin SciLin
- 6AiCuris’ Novel HSV Compound AIC316 Shows Efficacy in Phase II
- 7Bayer’s Novel Anticoagulant Xarelto now also Approved in the EU
- 8Nomad Bioscience: new plant biotechnology company founded to focus on biomaterials and biopharmaceuticals
- 9Biotech companies in the future among top 10 drug sellers / winners & losers of the pharmaceutical industry in the next decade
- 10M&A Trends in Pharma-Biotech: An Analysis of a Business Model
- Nanobiotix Appoints Bernd Muehlenweg as a Member of the Executive Board
- Novasep strengthens its management team
- Adocia reports positive phase II clinical results for the treatment of diabetic foot ulcer
- Biocitech residents continue to boost innovation in response to challenging economic times
- Enterome raises EUR five million in series A funding round
- Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin for Treatment of Type 2 Diabetes -
- Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease -
- Bayer acquires exclusive rights to Bioton’s insulin SciLin -
- M&A Trends in Pharma-Biotech: An Analysis of a Business Model -
- BioNTech AG acquires EUFETS AG -
